Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Nov 9, 2026)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed November 9, 2026
Period End
November 9, 2026
Security
CRL
In the record · 2016–202610-K1110-Q338-K118

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 8-K filed November 9, 2026. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International (CRL) has announced a definitive agreement to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 milliona in cash, plus potential performance-based payments up to $75 million.

This strategic acquisition is expected to close in the first half of 2027, subject to customary approvals. The transaction is designed to significantly strengthen CRL's bioanalysis capabilities, particularly in the high-growth clinical bioanalysis sector, and enhance its offering across the entire drug development lifecycle. This move aligns with CRL's "Pathway to Purpose" strategy, aiming to bolster scientific leadership, expand its presence in complex modalities, and improve client continuity from preclinical to clinical testing.

The acquired operations include two sites in Exton, PA, approximately 150,000 square feet, and employ around 340 people. Frontage's bioanalysis and DMPK businesses represented about 40%b of their total 2025 revenue.

CRL anticipates the acquired businesses will grow in line with the projected bioanalysis sector growth. While expected to be neutral to non-GAAP EPS in 2027, the acquisition is projected to be accretive thereafter, with financing to be drawn from the company's credit facility and available cash.

Key Highlights

  1. Charles River Laboratories (CRL) to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations for approximately $470 million in cash plus up to $75 million in potential performance-based payments.
  2. The acquisition significantly expands CRL's capabilities in clinical bioanalysis, a high-growth area within drug development.
  3. The deal is expected to close in the first half of 2027, pending shareholder and regulatory approvals.
  4. This strategic move aligns with CRL's "Pathway to Purpose" strategy, enhancing its service offering across the full drug development lifecycle.
  5. The acquired entities comprise two sites in Exton, Pennsylvania, encompassing approximately 150,000 sq ft and employing around 340 individuals.
  6. The transaction is projected to be neutral to non-GAAP EPS in 2027 and accretive thereafter.
  7. Financing for the acquisition will be sourced from CRL's existing credit facility and available cash.

Frequently Asked Questions

  1. What is the primary strategic rationale behind CRL's acquisition of Frontage's bioanalysis and DMPK operations?

    The primary strategic rationale is to significantly expand Charles River's capabilities in the high-growth clinical bioanalysis sector, strengthen its scientific leadership in complex modalities and biologics, and enhance its ability to support clients across the entire drug development lifecycle, from early research through clinical development. This aligns with their "Pathway to Purpose" strategy.

  2. What is the financial impact of this acquisition on Charles River Laboratories?

    The transaction is expected to be neutral to non-GAAP earnings per share in 2027 and accretive thereafter. Acquisition-related costs, such as amortization of intangible assets and advisory fees, are excluded from non-GAAP measures.

  3. How will the acquisition be financed?

    The acquisition and associated fees are expected to be financed through Charles River's existing credit facility and available cash.

  4. What are the key components of the acquired business from Frontage Holdings?

    The acquired components are Frontage's bioanalysis and DMPK (drug metabolism and pharmacokinetics) operations located in Exton, Pennsylvania. This includes laboratory testing sites providing bioanalysis, biomarker, and DMPK testing services, primarily for clinical development programs. It also includes a CLIA-certified central laboratory.